21 research outputs found
Nanovehículos basados en albúmina para terapia contra el cáncer
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Farmacia, leída el 15-12-2021Cancer is one of the major health problems worldwide and suitable therapies with enhanced efficacy and reduced side effects are hence being searched. In recent years, nanocarriers are gaining tremendous attention for the delivery of various therapeutic agents (both chemotherapeutics and nucleic acids) in cancer therapy. They offer multiple advantages, including improved drug delivery, targeted accumulation due to enhanced permeability and retention (EPR) effect, controlled release, improvement of circulation half-lives, biodistribution, and efficacy of encapsulated cargos, and flexibility in administration routes.This thesis is focused on the use of albumin-based nanocarriers for cancer therapy. Albumin is a versatile protein and provides biocompatibility, tumor specificity, the possibility for surface modification, and reduces toxicity. Some of the widely investigated albumin nanocarriers include polyplexes, nanoconjugates, and nanoparticles. Despite their broad potential in oncology, many studies still need to be done regarding their safety and tumor targeting enhancement. Anyhow, the potential of albumin nanocarriers is clearly supported by the FDA and EMA approved formulation, Abraxane, which is currently used for metastatic breast cancer. Therefore, further developments based on related strategies can have a dramatic impact on cancer therapy...El cáncer es uno de los principales problemas de salud en todo el mundo y la busqueda de terapias con mejor eficacia y menores efectos secundarios es un reto prioritario para la sociedad. En este sentido, en los últimos años, los nanovehiculos han mostrado excelentes propiedades para la administración de varios agentes terapéuticos (tanto quimioterapéuticos como ácidos nucleicos) en la terapia del cáncer. Estos sistemas ofrecen varias ventajas, como son una administración mejorada del fármaco, acumulación dirigida debido al efecto de permeabilidad y retención (EPR), liberación controlada, mejora de la vida media de la circulación, biodistribución y eficacia de las cargas encapsuladas y flexibilidad en las vías de administración. Esta tesis se centra en el uso de nanovehiculos a base de albúmina para la terapia del cáncer. La albúmina es una proteína versátil y proporciona biocompatibilidad, especificidad tumoral, la posibilidad de modificación de la superficie y reduce la toxicidad. Algunos de los nanopovehiculos de albúmina ampliamente investigados incluyen polyplexes, nanoconjugados y nanopartículas. A pesar de su amplio potencial en oncología, aún deben realizarse muchos estudios en términos de estudios de seguridad y mejora de la orientación tumoral. En este sentido merece la pena recordar que el potencial de los nanovehiculos de albúmina ya se refleja en una formulación aprobada por la FDA y la EMA, el Abraxane, utilizado para el cáncer de mama metastásico. Por tanto, es de esperar que futuros desarrollos basados en estos sistemas tengan un gran impacto en las terapias contra el cáncer...Fac. de FarmaciaTRUEunpu
Albumin-based nanocarriers for cancer therapy
Cancer is one of the major health problems worldwide and suitable therapies with enhanced efficacy and reduced side effects are hence being searched. In recent years, nanocarriers are gaining tremendous attention for the delivery of various therapeutic agents (both chemotherapeutics and nucleic acids) in cancer therapy. They offer multiple advantages, including improved drug delivery, targeted accumulation due to enhanced permeability and retention (EPR) effect, controlled release, improvement of circulation half-lives, biodistribution, and efficacy of encapsulated cargos, and flexibility in administration routes.This thesis is focused on the use of albumin-based nanocarriers for cancer therapy. Albumin is a versatile protein and provides biocompatibility, tumor specificity, the possibility for surface modification, and reduces toxicity. Some of the widely investigated albumin nanocarriers include polyplexes, nanoconjugates, and nanoparticles. Despite their broad potential in oncology, many studies still need to be done regarding their safety and tumor targeting enhancement. Anyhow, the potential of albumin nanocarriers is clearly supported by the FDA and EMA approved formulation, Abraxane, which is currently used for metastatic breast cancer. Therefore, further developments based on related strategies can have a dramatic impact on cancer therapy..
pH-responsive nano-self-assemblies of the anticancer drug 2-hydroxyoleic acid
pH-responsive lipid nanocarriers have the potential to selectively target the acidic extracellular pH environment of cancer tissues and may further improve the efficacy of chemotherapeutics by minimizing their toxic side-effects. Here, we present the design and characterization of pH-sensitive nano-self-assemblies of the poorly water-soluble anticancer drug 2-hydroxyoleic acid (2OHOA) with glycerol monooleate (GMO). pH- triggered nanostructural transformations from 2OHOA/GMO nanoparticles with an internal inverse hexagonal structure (hexosomes) at pH around 2.0–3.0, via nanocarriers with an internal inverse bicontinuous cubic structure (cubosomes) at pH 2.0–4.5, to vesicles at pH 4.5–7.4 were observed with synchrotron small-angle X-ray scattering, and cryogenic transmission electron microscopy. ζ-potential measurements highlight that the pH-driven deprotonation of the carboxylic group of 2OHOA, and the resulting charge-repulsions at the lipid–water interface account for these nanostructural alterations. The study provides detailed insight into the pH-dependent self-assembly of 2OHOA with GMO in excess buffer at physiologically relevant pH values, and discusses the effects of pH alterations on modulating their nanostructure. The results may guide the further development of pH-responsive anticancer nanocarriers for the targeted delivery of chemotherapeutics to the local microenvironment of tumor cells
Albumin-Based Nanoparticles for the Delivery of Doxorubicin in Breast Cancer
Albumin-based nanoparticles are an emerging platform for the delivery of various chemotherapeutics because of their biocompatibility, safety, and ease of surface modification for specific targeting. The most widely used method for the preparation of albumin nanoparticles is by desolvation process using glutaraldehyde (GLU) as a cross-linker. However, limitations of GLU like toxicity and interaction with drugs force the need for alternative cross-linkers. In the present study, several cross-linking systems were evaluated for the preparation of Bovine Serum Albumin (BSA) nanoparticles (ABNs) encapsulating Doxorubicin (Dox). Based on the results obtained from morphological characterization, in vitro release, and therapeutic efficacy in cells, N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)-modified ABNs (ABN-SPDP) was chosen. Since ABN-SPDP are formed with disulfide linkage, the drug release is facilitated under a highly reducing environment present in the tumor sites. The cytotoxicity studies of those ABN-SPDP were performed in three different breast cell lines, highlighting the mechanism of cell death. The Dox-encapsulated ABN-SPDP showed toxicity in both the breast cancer cells (MCF-7 and MDA-MB-231), but, remarkably, a negligible effect was observed in non-tumoral MCF-10A cells. In addition to the hydrophilic Dox, this system could be used as a carrier for hydrophobic drugs like SN38. The system could be employed for the preparation of nanoparticles based on human serum albumin (HSA), which further enhances the feasibility of this system for clinical use. Hence, the albumin nanoparticles developed herein present an excellent potential for delivering various drugs in cancer therapy
Albumin Nanostructures for Nucleic Acid Delivery in Cancer: Current Trend, Emerging Issues, and Possible Solutions
Cancer is one of the major health problems worldwide, and hence, suitable therapies with enhanced efficacy and reduced side effects are desired. Gene therapy, involving plasmids, small interfering RNAs, and antisense oligonucleotides have been showing promising potential in cancer therapy. In recent years, the preparation of various carriers for nucleic acid delivery to the tumor sites is gaining attention since intracellular and extracellular barriers impart major challenges in the delivery of naked nucleic acids. Albumin is a versatile protein being used widely for developing carriers for nucleic acids. It provides biocompatibility, tumor specificity, the possibility for surface modification, and reduces toxicity. In this review, the advantages of using nucleic acids in cancer therapy and the challenges associated with their delivery are presented. The focus of this article is on the different types of albumin nanocarriers, such as nanoparticles, polyplexes, and nanoconjugates, employed to overcome the limitations of the direct use of nucleic acids in vivo. This review also highlights various approaches for the modification of the surface of albumin to enhance its transfection efficiency and targeted delivery in the tumor sites
Temperature triggering of kinetically trapped self-assemblies in citrem-phospholipid nanoparticles
Citrem-phosphatidylcholine nano-self-assemblies: solubilization of bupivacaine and its role in triggering a colloidal transition from vesicles to cubosomes and hexosomes
Spectral energy and angular distributions of bremsstrahlung radiation produced by 3.5 keV electrons in scattering with a free SF
Absolute double differential cross sections (DDCS) of bremsstrahlung (BS) radiation produced by 3.5 keV electrons in scattering with a free SF6 molecule were measured by using a Si-PIN photodiode detector in the angular detection range of 45°−110° relative to the direction of incident electrons. Angular distributions of the BS photons are found to be anisotropic. The experimental DDCS spectra are compared with the theoretical calculations obtained from atomic-field BS formulations of Kissel–Quarles–Pratt (KQP) using the “additivity hypothesis”. A fair agreement is observed between the measured results and those obtained from the KQP calculations for both the energy and the angular spectral distributions of BS radiation. The measured anisotropy of bremsstrahlung radiation is reproduced reasonably well by a modified Sommerfeld formula, if the relative velocity β is chosen to be half of the incident electron velocity β0. The measured anisotropy may be described by a parameter P, which is compared with the degree of polarisation obtained from theoretical calculations. Further, it is noted that the molecular weight, geometry and the number of constituent atoms present in the considered molecule do not seem to influence the usefulness of “additivity hypothesis”. In conclusion, the present results have once again corroborated the validity of “additivity hypothesis” for predicting the spectral distributions of molecular bremsstrahlung produced by keV-electrons
Electron excited multiply charged argon ions studied by means of an energy resolved electron-ion coincidence technique
Multiply charged argon ions produced from decay of L-shell hole states by impact of a continuous beam of 3.5 keV electrons are studied for the first time using an energy resolved electron-ion coincidence technique. The TOF spectra of argon ions are measured in coincidence with 18-energy selected electrons emitted in a wide energy range (126–242 eV). The coincidence measurement between the energy selected electrons and the correlated ions specifies the individual decay channel for various multiply charged ions. New experimental data are obtained and reported on the correlation probability for production of argon ions with charge states 1+ to 4+ as a function of ejected electrons in the considered energy range. The relative correlation probability of producing different charge state ions and corresponding physical processes involved in their production are presented and discussed. It has been found that the maximum probability for production of Ar2+ ions correlated to ejected Auger electrons in the energy range of 205–209 eV is 100%. No theoretical predictions are available to compare with these results. The present study shows further that not only the auto-ionization and normal Auger transitions but also several other decay processes including Coster-Kronig transitions followed by Auger cascades with a fraction of shake process play important role in producing ions with charge states 1+ to 4+